Qube Research & Technologies Ltd - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 70 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$16,818
-81.8%
21,561
-78.5%
0.00%
Q2 2023$92,639
+77.7%
100,150
+109.4%
0.00%
Q1 2023$52,128
+32.2%
47,824
+77.1%
0.00%
Q4 2022$39,421
-47.4%
27,001
-38.6%
0.00%
-100.0%
Q2 2022$75,000
+127.3%
43,966
+261.4%
0.00%0.0%
Q1 2020$33,00012,1670.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2022
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$1,501,2502.44%
NEA Management Company, LLC 17,079,779$18,616,9581.29%
Endurant Capital Management LP 1,660,835$1,810,3100.93%
Matrix Capital Management Company, LP 38,974,185$42,481,8620.58%
Long Focus Capital Management, LLC 5,435,439$5,924,6290.34%
PFM Health Sciences, LP 5,992,571$6,531,9020.29%
Key Client Fiduciary Advisors, LLC 321,155$350,0590.22%
DAFNA Capital Management LLC 351,064$382,6600.12%
Rock Springs Capital Management LP 2,787,845$3,038,7510.07%
Baker Brothers Advisors 9,830,877$10,715,6560.06%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders